IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2024
- 16 July 2024 - 1 mins read
Aggregated presentation by day and by market
| Purchases of own shares from July 8th to 12th 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/07/2024 | FR0010259150 | 6 650 | 111,0282 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/07/2024 | FR0010259150 | 2 700 | 110,9397 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/07/2024 | FR0010259150 | 350 | 111,1231 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/07/2024 | FR0010259150 | 300 | 111,2180 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/07/2024 | FR0010259150 | 4 900 | 109,7478 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/07/2024 | FR0010259150 | 2 100 | 109,6744 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/07/2024 | FR0010259150 | 5 382 | 108,6341 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/07/2024 | FR0010259150 | 2 000 | 108,7151 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/07/2024 | FR0010259150 | 1 487 | 110,1258 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/07/2024 | FR0010259150 | 299 | 110,1107 | CEUX |
| TOTAL | 26 168 | 109,9431 | ||||
Attachment
09 December 2024
1 mins read
Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
07 November 2024
1 mins read
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 October 2024
1 mins read
Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
18 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16 September 2024
9 mins read
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
15 September 2024
7 mins read
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
04 September 2024
1 mins read
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
30 August 2024
1 mins read
Testing video 1
30 August 2024
1 mins read
Testing video 3
30 August 2024
1 mins read